LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

Inicio・Lista de Acciones・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Cerrado

1.13 1.8

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.09

Máximo

1.17

Métricas clave
By Trading Economics
Ingresos	17M -26M
Empleados	171
EBITDA	19M -23M

Dividendos
By Dow Jones
Próximas Ganancias	26 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-34M 68M
Apertura anterior	-0.67
Cierre anterior	1.13

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.43 / 1.6 Soporte y Resistencia

Pliant Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

17 feb 2026, 23:44 UTC

Acciones populares

Stocks to Watch: La-Z-Boy, Palo Alto Networks, Caesars

17 feb 2026, 23:20 UTC

Ganancias

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps -- Update

17 feb 2026, 22:57 UTC

Ganancias

Santos Fiscal Year Net Profit Falls 33%, Nears Start of Alaska Project

17 feb 2026, 21:59 UTC

Ganancias

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps

17 feb 2026, 23:54 UTC

Charlas de Mercado

Nikkei May Rise as Fears About AI Disruption Ease -- Market Talk

17 feb 2026, 23:54 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

17 feb 2026, 23:54 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 feb 2026, 23:45 UTC

Charlas de Mercado

Suncorp's Outperformance of IAG Could Be Hard to Sustain -- Market Talk

17 feb 2026, 23:19 UTC

Ganancias

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17 feb 2026, 23:15 UTC

Ganancias

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17 feb 2026, 22:58 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Netflix Would Operate Warner's Studios, HBO Largely the Same -- Market Talk

17 feb 2026, 22:58 UTC

Adquisiciones, fusiones, absorciones

BlueScope Steel: Board Committed to Optimizing Value For Shareholders

17 feb 2026, 22:57 UTC

Adquisiciones, fusiones, absorciones

BlueScope Steel to Consider Revised SGH, Steel Dynamics Takeover Bid

17 feb 2026, 22:50 UTC

Adquisiciones, fusiones, absorciones

Agnico-Eagle Mines Acquired 662,780 Common Shrs of Maple Gold Mines at C$2.45 Per Common Shr >AEM.T

17 feb 2026, 22:44 UTC

Ganancias

Palo Alto Reports Strong Earnings. Its Stock Is Down. -- Barrons.com

17 feb 2026, 22:42 UTC

Ganancias

Santos FY Net Profit Falls 33%, Nears Start of Alaska Project

17 feb 2026, 22:36 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Netflix Sarandos: Paramount Causing Confusion Around Warner Deal -- Market Talk

17 feb 2026, 22:36 UTC

Ganancias

Santos Final Dividend 10.3 U.S. Cents/Security

17 feb 2026, 22:36 UTC

Ganancias

Santos FY Underlying Profit US$898 Million, Down 25%

17 feb 2026, 22:35 UTC

Ganancias

Santos FY Revenue US$4.94 Billion, Down 8%

17 feb 2026, 22:35 UTC

Ganancias

Correct: Santos FY Net Profit US$818 Million, Down 33%

17 feb 2026, 22:35 UTC

Adquisiciones, fusiones, absorciones

Berkshire Buys New York Times Stock; Sells Apple, Bank of America, Amazon In 4Q -- Barrons.com

17 feb 2026, 22:34 UTC

Ganancias

Santos FY Net Profit US$818 Billion, Down 33%

17 feb 2026, 22:02 UTC

Adquisiciones, fusiones, absorciones

Berkshire Pares Stakes in Apple and BofA, Adds New York Times Position -- Update

17 feb 2026, 21:50 UTC

Adquisiciones, fusiones, absorciones

Steel Dynamics: SGH Would Buy BlueScope, On-sell North American Operations to SDI, As Earlier Proposed

17 feb 2026, 21:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

17 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 feb 2026, 21:49 UTC

Adquisiciones, fusiones, absorciones

Steel Dynamics Says Revised Proposal Continues to Present Highly Strategic Opportunity For SDI Shareholders

17 feb 2026, 21:48 UTC

Adquisiciones, fusiones, absorciones

Steel Dynamics: BlueScope Offer a 56% Premium to 52-Week Volume Weighted Average Price

17 feb 2026, 21:48 UTC

Adquisiciones, fusiones, absorciones

Steel Dynamics: Consideration To Be Comprised Entirely of Cash

Comparación entre iguales

Cambio de precio

Pliant Therapeutics Inc Esperado

Consenso

By TipRanks

Vender

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.43 / 1.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.